Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
2022; Elsevier BV; Volume: 140; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2022-163335
ISSN1528-0020
AutoresShaji Kumar, Philippe Moreau, Nizar J. Bahlis, Thierry Façon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O’Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Z. Usmani,
Tópico(s)HIV/AIDS drug development and treatment
Referência(s)